History
# Registration date Revision Id
3 2020-01-22, 1398/11/02 123382
2 2018-12-03, 1397/09/12 71318
1 2018-11-29, 1397/09/08 68777
Changes made to previous revision
  • Help:

    Red color represents old content. It may be empty showing addition in the new version.
    Green color represents new content. It may be empty showing deletion in the new version.

    Inline Side by side
    Added new contents, deleted old contents, contents that are not changed.
    New table contents New table contents
    Old table contents Old table contents
    Unchanged contents Unchanged contents
    Added new contents, contents that are not changed.
    Deleted old contents, contents that are not changed.
    Old table contents Old table contents
    Unchanged contents Unchanged contents
    New table contents New table contents
    Unchanged contents Unchanged contents
  • Protocol summary

    This study is a parallel controlled clinical trial consists of twenty six patients. With a randomization software, laser treatment and treatment with intralesional injection of glucantime are randomly assigned to the patients.
    This study is a parallel controlled clinical trial on 30 cutaneous leishmaniasis patients. With a randomization software, laser treatment and treatment with intralesional injection of glucantime are randomly assigned to the patients.
    این کارآزمایی بالینی دارای گروه کنترل، با گروههای موازی و بدون کورسازی صورت می گیرد که با استفاده از روش نمونه گیری در دسترس، 26 بیمار وارد مطالعه می شوند. با استفاده از نرم افزار راندوم سازی، درمان لیزر و درمان گلوکانتیم داخل ضایعه به بیماران تخصیص داده می شود.
    این کارآزمایی بالینی دارای گروه کنترل، با گروههای موازی و بدون کورسازی صورت می گیرد که با استفاده از روش نمونه گیری در دسترس، 30 بیمار وارد مطالعه می شوند. با استفاده از نرم افزار راندوم سازی، درمان لیزر و درمان گلوکانتیم داخل ضایعه به بیماران تخصیص داده می شود.
    Blinding is not done in this study. 26 patients with leishmaniasis who have a maximum lesion number of 3 and are refereed to Ghaem hospital in Mashhad enter the study. Follow-ups are carried out at intervals of 1,5, 3 and 6 months after the first treatment session.
    Blinding is not done in this study. 26 patients with leishmaniasis who have a maximum lesion number of 3 and are refereed to Ghaem hospital in Mashhad enter the study. Follow-ups are carried out at intervals of 3 and 6 months after the first treatment session.
    در این مطالعه کورسازی صورت نمیگیرد. 26 بیمار مبتلا به سالک با حداکثر 3 ضایعه مراجعه کننده به بیمارستان قائم مشهد وارد مطالعه می شوند. فالواپ پس از 1.5 و3 و 6 ماه بعد از اولین جلسه درمان صورت خواهد گرفت.
    در این مطالعه کورسازی صورت نمیگیرد. 30 بیمار مبتلا به سالک با حداکثر 3 ضایعه مراجعه کننده به بیمارستان قائم مشهد وارد مطالعه می شوند. فالواپ 3 و 6 ماه بعد از اولین جلسه درمان صورت خواهد گرفت.
    Intervention group:13 patients with acute urban leishmaniasis with less than 3-month treatment time will be placed under treatment with IPL laser device every 2 weeks (up to 4 sessions). The treatment of first session for the intervention group is carried out using laser Palomar system with 38-40 J / cm2 fluence. Afterwards, the parameters of the device in each session will be set aiming at creating purpura and ecchymorous. Control group: Patients with acute urban leishmaniasis will be treated with intralesional injection of glucantime weekly for up to 8-10 weeks.
    Intervention group: patients with acute urban leishmaniasis with less than 3-month treatment time will be placed under treatment with IPL laser device every 2 weeks (up to 6 sessions). The treatment of first session for the intervention group is carried out using laser Palomar system with 38-40 J / cm2 fluence. Afterwards, the parameters of the device in each session will be set aiming at creating purpura and ecchymorous. Control group: Patients with acute urban leishmaniasis will be treated with intralesional injection of glucantime weekly for up to 10 weeks.
    گروه مداخله: 13بیمار مبتلا به سالک شهری حاد با سیر کمتر از 3 ماه تحت درمان با دستگاه لیزر IPL هر 2 هفته یکبار (تا 4 جلسه) قرار داده خواهند شد که با استفاده از سیستم لیزر پالومار با فلوئنس J/cm2 38-40 درمان جلسه اول شروع می شود و سپس تنظیم پارامترهای دستگاه در هر جلسه با هدف ایجاد پورپورا و اکیمور انجام خواهندشد. گروه کنترل: 13 بیمار مبتلا به سالک شهری حاد تحت درمان با گلوکانتیم داخل ضایعه بصورت هفتگی تا 10-8 هفته قرار خواهند گرفت.
    گروه مداخله: بیماران مبتلا به سالک شهری حاد با سیر کمتر از 3 ماه تحت درمان با دستگاه لیزر IPL هر 2 هفته یکبار (تا 6 جلسه) قرار داده خواهند شد که با استفاده از سیستم لیزر پالومار با فلوئنس J/cm2 38-40 درمان جلسه اول شروع می شود و سپس تنظیم پارامترهای دستگاه در هر جلسه با هدف ایجاد پورپورا و اکیمور انجام خواهندشد. گروه کنترل: بیماران مبتلا به سالک شهری حاد تحت درمان با گلوکانتیم داخل ضایعه بصورت هفتگی تا 10 هفته قرار خواهند گرفت.
  • General information

    No
    No
    empty
    30
    empty
    2018-09-15, 1397/06/24
    empty
    2019-05-02, 1398/02/12
    empty
    2019-12-05, 1398/09/14
    empty
    Completion of trial and changes in actual sample size, as well as extended treatments.
    empty
    اتمام کارازمایی بالینی و تغییراتی در حجم نمونه نهایی به همراه افزایش طول درمان بیماران نسبت به ثبت اولیه.
    Comparing the therapeutic effect of IPL laser with effective wavelength spectrum on vascular lesions and intralesional Glucantime in treatment patients with acute cutaneous leishmaniasis
    Comparing the therapeutic effect of IPL with wavelength spectrum effective on vascular lesions and intralesional Glucantime in treatment of patients with acute cutaneous leishmaniasis
    مقایسه اثر لیزر IPL با طیف طول موج موثر بر ضایعات عروقی و گلوکانتیم داخل ضایعه در درمان مبتلایان به لشمانیوز جلدی حاد
    مقایسه اثر IPL با طیف طول موج موثر بر ضایعات عروقی و گلوکانتیم داخل ضایعه در درمان مبتلایان به لشمانیوز جلدی حاد
  • Primary outcomes

    #1
    Photos are evaluated at each treatment session and then 1.5, 3, and 6 months after the first treatment session.
    Photos are evaluated at each treatment session and then 3 and 6 months after the first treatment session.
    عکس ها در هر جلسه درمان و سپس 1.5 و 3 و 6 ماه بعد از اولین جلسه درمانی ارزیابی می شوند.
    عکس ها در هر جلسه درمان و سپس در فالوآپ 3 و 6 ماه بعد از اولین جلسه درمانی ارزیابی می شوند.
    #2
    Diameter of lesion induration is evaluated at each treatment session and then 1.5, 3, and 6 months after the first treatment session.
    Diameter of lesion induration is evaluated at each treatment session and then 3 and 6 months after the first treatment session.
    قطر اندوراسیون ضایعه در هر جلسه درمان و سپس 1.5 و 3 و 6 ماه بعد از اولین جلسه درمانی ارزیابی می شود.
    قطر اندوراسیون ضایعه در هر جلسه درمان و سپس در فالوآپ 3 و 6 ماه بعد از اولین جلسه درمانی ارزیابی می شود.
  • Intervention groups

    #1
    Intervention group:13 patients with acute urban leishmaniasis with less than 3 months treatment time will be placed under treatment with IPL laser device every 2 weeks (up to 4 sessions)
    Intervention group: patients with acute urban leishmaniasis with less than 3 months treatment time will be placed under treatment with IPL device every 2 weeks (up to 6 sessions)
    گروه مداخله: 13 بیمار مبتلا به سالک شهری حاد با سیر کمتر از 3 ماه تحت درمان با دستگاه لیزر IPL هر 2 هفته یکبار (تا 4 جلسه) قرار خواهند گرفت.
    گروه مداخله: بیماران مبتلا به سالک شهری حاد با سیر کمتر از 3 ماه تحت درمان با دستگاه IPL هر 2 هفته یکبار (تا 6 جلسه) قرار خواهند گرفت.
    #2
    Control group: Patients with acute urban leishmaniasis will be treated with intralesional injection of glucantime weekly for up to 8-10 weeks
    Control group: patients with acute urban leishmaniasis will be treated with intralesional injection of glucantime weekly for up to 10 weeks (11 sessions).
    گروه کنترل: بیمار مبتلا به سالک شهری حاد تحت درمان با گلوکانتیم داخل ضایعه بصورت هفتگی تا 10-8 هفته قرار خواهند گرفت.
    گروه کنترل: بیماران مبتلا به سالک شهری حاد تحت درمان با گلوکانتیم داخل ضایعه بصورت هفتگی تا 10 هفته (ماکزیمم 11 جلسه) قرار خواهند گرفت.

Protocol summary

Study aim
determination of the therapeutic effect of IPL laser with effective wavelength spectrum for vascular lesions on active lesions of cutaneous leishmaniasis
Design
This study is a parallel controlled clinical trial on 30 cutaneous leishmaniasis patients. With a randomization software, laser treatment and treatment with intralesional injection of glucantime are randomly assigned to the patients.
Settings and conduct
Blinding is not done in this study. 26 patients with leishmaniasis who have a maximum lesion number of 3 and are refereed to Ghaem hospital in Mashhad enter the study. Follow-ups are carried out at intervals of 3 and 6 months after the first treatment session.
Participants/Inclusion and exclusion criteria
Inclusion Criteria: Cases with confirmed urban leishmaniasis based on clinical presentation and skin smear result, indication of topical treatment, maximum lesion number of 3, duration of the disease is less than 3 months, no laceration on the lesion. exclusion criteria: pregnancy, photosensitivity, positive Kobner test skin disease
Intervention groups
Intervention group: patients with acute urban leishmaniasis with less than 3-month treatment time will be placed under treatment with IPL laser device every 2 weeks (up to 6 sessions). The treatment of first session for the intervention group is carried out using laser Palomar system with 38-40 J / cm2 fluence. Afterwards, the parameters of the device in each session will be set aiming at creating purpura and ecchymorous. Control group: Patients with acute urban leishmaniasis will be treated with intralesional injection of glucantime weekly for up to 10 weeks.
Main outcome variables
diameter of lesion induration ; photography

General information

Reason for update
Completion of trial and changes in actual sample size, as well as extended treatments.
Acronym
IRCT registration information
IRCT registration number: IRCT20140414017271N5
Registration date: 2018-11-29, 1397/09/08
Registration timing: registered_while_recruiting

Last update: 2020-02-25, 1398/12/06
Update count: 2
Registration date
2018-11-29, 1397/09/08
Registrant information
Name
Yalda Nahidi
Name of organization / entity
department of dermatology, Ebne Sina St, Emam Reza hospital
Country
Iran (Islamic Republic of)
Phone
+98 51 1802 2490
Email address
nahidiy@mums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2018-09-15, 1397/06/24
Expected recruitment end date
2020-03-19, 1398/12/29
Actual recruitment start date
2018-09-15, 1397/06/24
Actual recruitment end date
2019-05-02, 1398/02/12
Trial completion date
2019-12-05, 1398/09/14
Scientific title
Comparing the therapeutic effect of IPL with wavelength spectrum effective on vascular lesions and intralesional Glucantime in treatment of patients with acute cutaneous leishmaniasis
Public title
Therapeutic effect of laser on leishmaniasis
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Cases with confirmed urban leishmaniasis based on clinical presentation and skin smear result Indication for topical treatment Maximum lesion number of 3 Disease duration less than 3 months No damage to the lesion Informed consent to participate in the study
Exclusion criteria:
pregnancy photosensitivity positive Kobner test skin disease
Age
No age limit
Gender
Both
Phase
2-3
Groups that have been masked
No information
Sample size
Target sample size: 26
Actual sample size reached: 30
Randomization (investigator's opinion)
Randomized
Randomization description
Patients will be randomly divided into two groups based on the list of random numbers generated by a computer.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Mashhad University of Medical Sciences
Street address
Central Building of Mashhad University of Medical Sciences (Ghorshi), Daneshgah 16, Daneshgah street
City
Mashhad
Province
Razavi Khorasan
Postal code
9177899191
Approval date
2018-07-25, 1397/05/03
Ethics committee reference number
IR.MUMS.MEDICAL.REC.1397.398

Health conditions studied

1

Description of health condition studied
acute cutaneous leishmaniasis
ICD-10 code
B55.1
ICD-10 code description
Cutaneous leishmaniasis

Primary outcomes

1

Description
Photography of lesion
Timepoint
Photos are evaluated at each treatment session and then 3 and 6 months after the first treatment session.
Method of measurement
Camera

2

Description
diameter of lesion induration
Timepoint
Diameter of lesion induration is evaluated at each treatment session and then 3 and 6 months after the first treatment session.
Method of measurement
Caliper

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: patients with acute urban leishmaniasis with less than 3 months treatment time will be placed under treatment with IPL device every 2 weeks (up to 6 sessions)
Category
Treatment - Devices

2

Description
Control group: patients with acute urban leishmaniasis will be treated with intralesional injection of glucantime weekly for up to 10 weeks (11 sessions).
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Dermatology clinic, Imam Raza Hospital
Full name of responsible person
Zahra Tafazzoli
Street address
Ghaem Hospital, Ahmad Abad Avenue
City
Mashhad
Province
Razavi Khorasan
Postal code
9173699199
Phone
+98 51 3801 2493
Email
Tafazzoliz951@mums.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Dr Mohsen Tafaghodi
Street address
Central Building of Mashhad University of Medical Sciences (Ghorshi), Daneshgah 16, Daneshgah street
City
Mashhad
Province
Razavi Khorasan
Postal code
345 - 91357
Phone
+98 51 3841 1538
Email
ramresearch@mums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Mashhad University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Zahra Tafazzoli
Position
Resident
Latest degree
Medical doctor
Other areas of specialty/work
Dermatology
Street address
Emam Reza hospital, Emam Reza Sq, Ebne-sina Ave
City
Mashhad
Province
Razavi Khorasan
Postal code
9137913316
Phone
+98 51 3802 5732
Email
Tafazzoliz951@mums.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Dr Yalda Nahidi
Position
Associate professor
Latest degree
Specialist
Other areas of specialty/work
Dermatology
Street address
Emam Reza hospital, Ebne-sina Ave,Emam Reza Sq, Mashhad
City
Mashhad
Province
Razavi Khorasan
Postal code
9137913316
Phone
+98 51 3802 5732
Email
nahidiy@mums.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Dr Yalda Nahidi
Position
Associate professor
Latest degree
Specialist
Other areas of specialty/work
Dermatology
Street address
Emam Reza hospital, Ebne-sina Ave,Emam Reza Sq, Mashhad
City
Mashhad
Province
Razavi Khorasan
Postal code
9137913316
Phone
+98 51 3802 5732
Email
nahidiy@mums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Not applicable
Data Dictionary
Not applicable
Title and more details about the data/document
All data can be shared after patients are made unidentifiable.
When the data will become available and for how long
Data can be accessible 6 months after results are published.
To whom data/document is available
Data will be available for researchers at universities and other scientific institutes.
Under which criteria data/document could be used
Carrying out analysis on data is permitted.
From where data/document is obtainable
Data can be accessible through sending an email to the corresponding author.
What processes are involved for a request to access data/document
After sending a request email to the corresponding author, data will be sent in 1 month.
Comments
Loading...